Multistep tumorigenesis of multiple myeloma: its molecular delineation.
Multiple myeloma (MM) is an incurable malignant neoplasm affecting terminally differentiated B-cells. It derives from post-germinal center B-cells and develops as a result of multistep tumorigenic events, because approximately one third of all MM cases have a history of preceding monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma. MM terminates in the formation of extramedullary invasion or in secondary plasma cell leukemia. To account for this clinical experience, investigators have found that intrinsic chromosomal instability followed by complex chromosomal translocations/deletions plays a crucial role in the development from MGUS to MM. Representative aberrations include chromosomal rearrangements involving 14q32 loci and deletion at the long arm of chromosome 13. Contributing to the progression of MM itself are genomic instability and altered methylation of the specific gene promoters. The former results in activation of specific oncogenes such as RAS and FGFR3 or in inactivation of p53, and the latter results in inactivation of tumor suppressor genes, including p16. An accurate understanding of each of these molecular events should help clarify the development of specific molecular targeting therapies based on the differences in dysfunctional signaling pathways found in the cells of all MM patients.
Department of Internal Medicine & Molecular Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan. iida@med.nagoya-cu.ac.jp
Shinsuke
S
Iida
Ryuzo
R
Ueda
D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D002869:Chromosome Aberrations; D018450:Disease Progression; D006801:Humans; D009101:Multiple Myeloma / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction